Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02885272 · ClinicalTrials.gov registry record · Early Phase 1
FDG PET Imaging in Diagnosing Patients With Glioblastoma
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT02885272: Completed Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02885272 is a Early Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02885272, a Early Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This early phase I trial studies the how well fluorodeoxyglucose F-18 (FDG) positron emission tomography (PET) imaging works in diagnosing patients with confirmed or suspected glioblastoma. Diagnostic procedures, such as FDG PET, may help find and diagnose glioblastoma.
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Positron Emission Tomography
- RADIATION Fludeoxyglucose F-18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-10-28 |
| Est. Completion | 2022-07-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02885272
The ClinicalTrials.gov registry entry for NCT02885272 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Computed Tomography is the first listed.
NCT02885272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02885272 about?
NCT02885272 is a clinical study titled "FDG PET Imaging in Diagnosing Patients With Glioblastoma". This early phase I trial studies the how well fluorodeoxyglucose F-18 (FDG) positron emission tomography (PET) imaging works in diagnosing patients with confirmed or suspected glioblastoma. Diagnostic procedures, such as FDG PET, may help find and diagnose glioblastoma.
What is the current status of trial NCT02885272?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2016-10-28. Estimated completion is 2022-07-12.
What interventions are being tested in trial NCT02885272?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Fludeoxyglucose F-18 (RADIATION).
Who is sponsoring clinical trial NCT02885272?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.